Due to Easter holiday, all delivery service requests will not be processed on Friday, April 10, 2020. Regular delivery schedule will resume on Monday, April 13, 2019.

Sorafenib(R01-900)

  • $50.00


FOR BULK ORDER REQUESTS PLEASE CONTACT US

Description :RAF1 kinase inhibitor (and others)

Species :

Tag :

Expression System:

Sequence :

CAS Registry Number :284461-73-0

Molecular Formula :C21H16ClF3N4O3

Appearance :Off-white powder

Melting Point :204-206oC

Molecular Weight :464.8

Purity :>99% (TLC); NMR (Conforms)

Solubilization :Soluble in DMSO (200 mg/ml); or Ethanol (3 mg/ml)

Aliases :
1. 4-(4-(3-(4-chloro-3 (trifluoromethyl) phenyl) ureido) phenoxy)-N-methylpicolinamide

2. BAY 43-9006

Storage and Stability :Store desiccated as supplied at -20o for up to 2 years. Store solutions at -20oC for up to 1 month.

Scientific Background :Initially developed as a Raf kinase inhibitor, IC50 = 6 nM, but has been shown to inhibit many receptor tyrosine kinases including BRAF (IC50 = 22 nM); VEGFR-2 (IC50 = 90 nM); VEGFR-3 (IC50 = 20 nM); PDGFR-beta (IC50 = 57 nM); Flt3 (IC50 = 58 nM); c-KIT (IC50 = 68 nM); FGFR-1 (IC50 = 580 nM) (1). Paradoxically more potent in a cellular assay (IC50 = 20 nM) compared to an isolated enzyme assay (IC50 = 107 nM) for c-Fms (2). Inhibits activation of MAPK pathway and ERK phosphorylation (3). Induces caspase-independent apoptosis in melanoma cells (4). Clinically useful anticancer agent.

References :
1. SM Wilhelm et al. Cancer Res. 2004 64:7099

2. J Guo et al. Mol. Cancer Ther. 2006 5:1007

3. SM Wilhelm et al. Proc. Am. Assoc. Cancer Res. 2003 44:106609

4. DJ Panka et al. Cancer Res. 2006 66:1611

Molecular Structure :

Product Sheets (By Lot #) :

T2257-67.pdf

Research Areas :Angiogenesis, Apoptosis/Autophagy, Cancer, Cardiovascular Disease, ERK/MAPK Pathway, Invasion/Metastasis, Neurobiology, Ser/Thr Kinases, Cancer, Neurobiology, Cardiovascular Disease, ERK/MAPK Pathway, Apoptosis/Autophagy, Angiogenesis, Invasion/Metastasis, Ser/Thr Kinases